Mabwell (Shanghai) Bioscience Co., Ltd. Announces IPO Offer Price and Key Dates

Summary of Key Points

• The Offer Price for Mabwell (Shanghai) Bioscience Co., Ltd.’s H Shares has been set at HK\$27.64 per Offer Share.
• The offering is exclusive of additional charges: brokerage fee (1%), SFC transaction levy (0.0027%), Stock Exchange trading fee (0.00565%), and AFRC transaction levy (0.00015%).
• Trading of the H Shares is expected to commence at 9:00 a.m. on Tuesday, April 28, 2026 on the Main Board of the Stock Exchange.
• H Shares will be traded in board lots of 200 shares each.
• The Company will publish the results of the allocation and the levels of interest and applications for both the International Offering and the Hong Kong Public Offering on Monday, April 27, 2026.
• The IPO is being conducted in accordance with Hong Kong regulatory requirements and is not available to investors in the United States due to regulatory restrictions.
• CITIC Securities (Hong Kong) Limited and Haitong International Capital Limited are acting as Joint Sponsors; CLSA Limited and Haitong International Securities Company Limited as Sponsor-Overall Coordinators; China Industrial Securities International Capital Limited and CMB International Capital Limited as Overall Coordinators.
• The Hong Kong Offer Shares are available only to the public in Hong Kong, with strict residency requirements.
• There is a possibility of termination of the Hong Kong Underwriting Agreement by the Overall Coordinators under certain circumstances, which could affect the offering.

Important Information for Shareholders & Potential Price Sensitive Factors

• Offer Price Determination: The final offer price of HK\$27.64 per share will directly impact the valuation and market debut of Mabwell’s H Shares.
• Trading Start Date: The commencement of trading on April 28, 2026 is a crucial milestone. Any delay or change in listing date could significantly impact investor confidence and share price.
• Allocation Results Announcement: The publication of allocation results on April 27, 2026 will provide transparency on demand for the IPO, which may influence aftermarket performance.
• Regulatory Risks: The announcement highlights the possibility of termination of the Hong Kong Underwriting Agreement if certain events occur before the listing. Such a termination could materially affect the IPO’s success and future trading.
• Residency Restrictions: Shares are only available to Hong Kong residents. International investors, especially from the United States, are excluded, which may affect liquidity and demand.
• Board Composition: The Board consists of experienced directors, including Dr. Liu Datao (Chairman), Mr. Tang Chunshan, Dr. Wu Hai, Mr. Hu Huiguo, Dr. Gui Xun (executive Directors), Mr. Wu Yufeng (non-executive Director), and several independent non-executive Directors. Leadership quality may affect investor perception and share value.

Detailed Timeline and Process

1. April 20, 2026: Prospectus issued, opening of the IPO process.
2. April 24, 2026: Offer Price determined and announced at HK\$27.64 per Offer Share.
3. April 27, 2026: Announcement of allocation results and levels of interest/applications.
4. April 28, 2026: Expected commencement of trading in H Shares on the Stock Exchange.

Potential Share Price Impact

The final offer price, demand for the shares (to be revealed in allocation results), and any developments related to underwriting (such as possible termination) are all potentially price-sensitive and could lead to significant movement in Mabwell’s share price upon listing. Investors should closely monitor these developments and ensure they are aware of all regulatory and procedural risks.

Additional Considerations

• Investors must read the full prospectus before making any investment decisions, as this announcement does not replace detailed disclosures.
• The offering is not available for U.S. investors, and no public offer will be made in the United States.
• All trading is subject to standard fees and levies as outlined above.

Board Statement

The announcement was issued by Mr. Hu Huiguo, Executive Director, on behalf of the Board of Mabwell (Shanghai) Bioscience Co., Ltd.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or an offer to purchase securities. Investors should consult the official prospectus and seek independent advice before making investment decisions. The information provided is based on company announcements and may be subject to change.

View MABWELL-B Historical chart here